1997
Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus)
Taylor J, Elsworth J, Roth R, Sladek J, Redmond D. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 1997, 81: 745-755. PMID: 9316026, DOI: 10.1016/s0306-4522(97)00214-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseSevere parkinsonismAdult male African green monkeysMale African green monkeysTetrahydropyridine-induced parkinsonismMPTP-induced parkinsonismIdiopathic Parkinson's diseaseNovel therapeutic treatmentsLong-term deficitsAfrican green monkeysGroups of animalsNon-human primatesMPTP treatmentParkinsonian monkeysMPTP administrationVervet monkeysFunctional deficitsInitial severityStable parkinsonismBehavioral deficitsAnimal modelsParkinsonismParkinsonian subjectsMPTPTherapeutic treatment
1991
The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys
Lawrence M, Redmond D, Elsworth J, Taylor J, Roth R. The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys. Life Sciences 1991, 49: pl229-pl234. PMID: 1836030, DOI: 10.1016/0024-3205(91)90299-q.Peer-Reviewed Original ResearchConceptsSCH 23390African green monkeysD1 antagonistHealthy African green monkeysGreen monkeysParkinsonian side effectsD1 receptor antagonistPoverty of movementSigns of parkinsonismSelective D1 antagonistFull D1 agonistParkinsonian signsReceptor antagonistD1 agonistD1 receptorsSystemic administrationParkinson's diseasePsychiatric disordersSide effectsMotor changesClinical useParkinsonismAntagonistBlink rateMonkeys
1990
MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys
Elsworth J, Deutch A, Redmond D, Sladek J, Roth R. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Research 1990, 513: 320-324. PMID: 2350702, DOI: 10.1016/0006-8993(90)90474-p.Peer-Reviewed Original ResearchConceptsVentral tegmental areaSubstantia nigraTegmental areaRetrorubral fieldParkinson's diseasePostencephalitic Parkinson's diseaseHomovanillic acid concentrationsMesostriatal dopaminergic systemIdiopathic Parkinson's diseaseAsymptomatic monkeysSymptomatic monkeysDA neuronsHVA concentrationsMPTP toxicityTreatment regimensDopaminergic systemDopamine concentrationsDA regionsDiseaseNigraDopamineParkinsonismMonkeysVervet monkeysRegimens
1988
Reversal of Experimental Parkinsonism in African Green Monkeys Following Fetal Dopamine Neuron Transplantation
Collier T, Redmond D, Roth R, Elsworth J, Sladek J. Reversal of Experimental Parkinsonism in African Green Monkeys Following Fetal Dopamine Neuron Transplantation. 1988, 211-218. DOI: 10.1007/978-1-4613-0759-4_27.Peer-Reviewed Original ResearchChronic L-DOPA administrationL-DOPA administrationAfrican green monkeysNeuron transplantationExperimental parkinsonismMotor symptomsNigrostriatal systemBrain dopamineMotor abnormalitiesPreferred treatmentParkinson's diseaseL-DOPAGreen monkeysDiseaseProgressive debilitationNeurotransmitter dopamineAdministrationDopamineParkinsonismTransplantationSymptomsAbnormalitiesBrainSupplementationChapter 64 Fetal dopamine neural grafts: extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in monkeys
Sladek J, Redmond D, Collier T, Blount J, Elsworth J, Taylor J, Roth R. Chapter 64 Fetal dopamine neural grafts: extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in monkeys. Progress In Brain Research 1988, 78: 497-506. PMID: 3266802, DOI: 10.1016/s0079-6123(08)60323-4.Peer-Reviewed Original ResearchConceptsDopamine neuronsTherapeutic interventionsHuman parkinsonismHost brainFunctional recoveryDopaminergic neuronsSubstantia nigraCell graftsDopamine levelsFetal brainGraft siteTrophic factorsHuman neuronsAnatomical substrateParkinsonismCerebellar tissueControl transplantsNeuronsGraftBrain activityPhenotype characteristicBrainInterventionTransplantationTransplant
1979
SELECTIVE MAO INHIBITION: A NEW STRATEGY IN THE TREATMENT OF PARKINSON'S DISEASE
Elsworth J, Glover V, Sandler M. SELECTIVE MAO INHIBITION: A NEW STRATEGY IN THE TREATMENT OF PARKINSON'S DISEASE. 1979, 1575-1577. DOI: 10.1016/b978-1-4832-8363-0.50482-1.Peer-Reviewed Original Research